Goodwill and Other Intangible Assets (Tables)

12 Months Ended

Dec. 31, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]

tangible asset amortization expense for the years ended December 31, 2019 through 2023 is estimated to be as follows:



(In millions)
2019	$	1,703
2020	1,544
2021	1,462
2022	1,392
2023	967

Changes in carrying amount of goodwill

The changes in the carrying amount of goodwill for the years ended December 31, 2018 and 2017 are as follows:



(In millions)	North America Segment			Europe Segment			Rest of World Segment			Total
Balance at December 31, 2016:
Goodwill	$	3,990.4		$	3,859.1		$	1,767.4		$	9,616.9
Accumulated impairment losses	(385.0		)	—			—			(385.0		)
	3,605.4			3,859.1			1,767.4			9,231.9
Acquisitions	92.2			—			—			92.2
Reclassifications ⁽¹⁾	(200.1		)	382.2			(182.1		)	—
Measurement period adjustments	—			7.7			—			7.7
Divestiture	—			(1.3		)	—			(1.3		)
Foreign currency translation	52.1			719.4			103.7			875.2
	3,549.6			4,967.1			1,689.0			10,205.7
Balance at December 31, 2017:
Goodwill	3,934.6			4,967.1			1,689.0			10,590.7
Accumulated impairment losses	(385.0		)	—			—			(385.0		)
	3,549.6			4,967.1			1,689.0			10,205.7
Foreign currency translation	(41.7		)	(309.7		)	(106.5		)	(457.9		)
	3,507.9			4,657.4			1,582.5			9,747.8
Balance at December 31, 2018
Goodwill	3,892.9			4,657.4			1,582.5			10,132.8
Accumulated impairment losses	(385.0		)	—			—			(385.0		)
	$	3,507.9		$	4,657.4		$	1,582.5		$	9,747.8

____________


⁽¹⁾	The reclassifications relate to the allocation of goodwill for the Meda acquisition.

Components of intangible assets

tangible assets consist of the following components at December 31, 2018 and 2017:



(In millions)	Weighted Average Life (Years)	Cost		Accumulated Amortization		Net Book Value
December 31, 2018
Product rights, licenses and other ⁽¹⁾	15	$	20,264.1	$	7,225.1	$	13,039.0
In-process research and development		625.6		—		625.6
		$	20,889.7	$	7,225.1	$	13,664.6
December 31, 2017
Product rights, licenses and other ⁽¹⁾	15	$	20,338.7	$	5,906.1	$	14,432.6
In-process research and development		813.2		—		813.2
		$	21,151.9	$	5,906.1	$	15,245.8

____________


⁽¹⁾	Represents amortizable intangible assets. Other intangibles consist principally of customer lists and contractual rights.

Product rights and licenses by therapeutic category

oduct rights and licenses are primarily comprised of the products marketed at the time of acquisition. These product rights and licenses relate to numerous individual products, the net book value of which, by therapeutic franchise, is as follows:



(In millions)	December 31, 2018		December 31, 2017
Central Nervous System and Anesthesia	$	2,148.9	$	2,453.7
Dermatology	2,125.7		2,393.0
Gastroenterology	1,790.9		2,050.0
Diabetes and Metabolism	1,232.4		1,425.6
Cardiovascular	1,541.9		1,779.5
Respiratory and Allergy	2,084.1		1,769.5
Infectious Disease	596.0		494.8
Oncology	206.0		380.1
Women's Healthcare	315.1		371.4
Immunology	258.8		301.5
Other ⁽¹⁾	694.9		970.1
	$	12,994.7	$	14,389.2

Finite-lived Intangible Assets Amortization Expense [Table Text Block]

ortization expense and intangible asset impairment charges, which are included as a component of amortization expense, which is classified primarily within cost of sales in the Consolidated Statements of Operations, for the years ended December 31, 2018, 2017 and 2016 was as follows:



	Year ended December 31,
(In millions)	2018		2017		2016
Intangible asset amortization expense	$	1,606.4	$	1,437.4	$	1,195.3
IPR&D intangible asset impairment charges	117.7		74.6		49.9
Finite-lived intangible asset impairment charges	106.3		6.2		18.4
Total intangible asset amortization expense (including impairment charges)	$	1,830.4	$	1,518.2	$	1,263.6